BACKGROUND: Maternal depression is associated with a higher incidence of behavioral problems in infants, but the effects of maternal depression as early as 1 month are not well characterized. The objective of this study is to determine the neurobehavioral effects of maternal depression on infants exposed and not exposed to methamphetamine (MA) using the NICU Network Neurobehavioral Scale (NNNS). METHODS: Four hundred twelve mother-infant pairs were enrolled (MA = 204) and only biological mothers with custody of their child were included in the current analysis. At the 1-month visit (n = 126 MA-exposed; n = 193 MA-unexposed), the Beck Depression Inventory-II (BDI-II) was administered, and the NNNS was administered to the infant. Exposure was identified by self-report and/or gas chromatography/mass spectroscopy confirmation of amphetamine and metabolites in newborn meconium. Unexposed subjects were matched, denied amphetamine use, and had negative meconium screens. General Linear Models tested the effects of maternal depression and prenatal MA exposure on NNNS, with significance accepted at P < .05. RESULTS: The MA group had an increased incidence of depression-positive diagnosis and increased depression scores on the BDI-II. After adjusting for covariates, MA exposure was associated with increased arousal and handling scores, and a decreased ability to self-regulate. Maternal depression was associated with higher autonomic stress and poorer quality of movement. No additional differences were observed in infants whose mothers were both depressed and used MA during pregnancy. CONCLUSIONS: Maternal depression is associated with neurodevelopmental patterns of increased stress and decreased quality of movement, suggesting maternal depression influences neurodevelopment in infants as young as 1 month.
BACKGROUND:Maternal depression is associated with a higher incidence of behavioral problems in infants, but the effects of maternal depression as early as 1 month are not well characterized. The objective of this study is to determine the neurobehavioral effects of maternal depression on infants exposed and not exposed to methamphetamine (MA) using the NICU Network Neurobehavioral Scale (NNNS). METHODS: Four hundred twelve mother-infant pairs were enrolled (MA = 204) and only biological mothers with custody of their child were included in the current analysis. At the 1-month visit (n = 126 MA-exposed; n = 193 MA-unexposed), the Beck Depression Inventory-II (BDI-II) was administered, and the NNNS was administered to the infant. Exposure was identified by self-report and/or gas chromatography/mass spectroscopy confirmation of amphetamine and metabolites in newborn meconium. Unexposed subjects were matched, denied amphetamine use, and had negative meconium screens. General Linear Models tested the effects of maternal depression and prenatal MA exposure on NNNS, with significance accepted at P < .05. RESULTS: The MA group had an increased incidence of depression-positive diagnosis and increased depression scores on the BDI-II. After adjusting for covariates, MA exposure was associated with increased arousal and handling scores, and a decreased ability to self-regulate. Maternal depression was associated with higher autonomic stress and poorer quality of movement. No additional differences were observed in infants whose mothers were both depressed and used MA during pregnancy. CONCLUSIONS:Maternal depression is associated with neurodevelopmental patterns of increased stress and decreased quality of movement, suggesting maternal depression influences neurodevelopment in infants as young as 1 month.
Authors: Rachel Zabaneh; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Amelia Arria; Marilyn Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Hai Lin; Charles Neal; Barry M Lester Journal: Am J Perinatol Date: 2011-08-04 Impact factor: 1.862
Authors: N D Volkow; L Chang; G J Wang; J S Fowler; Y S Ding; M Sedler; J Logan; D Franceschi; J Gatley; R Hitzemann; A Gifford; C Wong; N Pappas Journal: Am J Psychiatry Date: 2001-12 Impact factor: 18.112
Authors: Y Sekine; M Iyo; Y Ouchi; T Matsunaga; H Tsukada; H Okada; E Yoshikawa; M Futatsubashi; N Takei; N Mori Journal: Am J Psychiatry Date: 2001-08 Impact factor: 18.112
Authors: Barry M Lester; Edward Z Tronick; Linda LaGasse; Ronald Seifer; Charles R Bauer; Seetha Shankaran; Henrietta S Bada; Linda L Wright; Vincent L Smeriglio; Jing Lu; Loretta P Finnegan; Penelope L Maza Journal: Pediatrics Date: 2002-12 Impact factor: 7.124
Authors: Charles R Bauer; Seetha Shankaran; Henrietta S Bada; Barry Lester; Linda L Wright; Heidi Krause-Steinrauf; Vincent L Smeriglio; Loretta P Finnegan; Penelope L Maza; Joel Verter Journal: Am J Obstet Gynecol Date: 2002-03 Impact factor: 8.661
Authors: Edythe D London; Sara L Simon; Steven M Berman; Mark A Mandelkern; Aaron M Lichtman; Jennifer Bramen; Ann K Shinn; Karen Miotto; Jennifer Learn; Yun Dong; John A Matochik; Varughese Kurian; Thomas Newton; Roger Woods; Richard Rawson; Walter Ling Journal: Arch Gen Psychiatry Date: 2004-01
Authors: Marcela C Smid; Torri D Metz; Gwen A McMillin; Lisa Mele; Brian M Casey; Uma M Reddy; Ronald J Wapner; John M Thorp; George R Saade; Alan T N Tita; Emily S Miller; Dwight J Rouse; Baha Sibai; Maged M Costantine; Brian M Mercer; Steve N Caritis Journal: Obstet Gynecol Date: 2022-01-01 Impact factor: 7.623
Authors: Lynne M Smith; Sabrina Diaz; Linda L LaGasse; Trecia Wouldes; Chris Derauf; Elana Newman; Amelia Arria; Marilyn A Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: Neurotoxicol Teratol Date: 2015-07-23 Impact factor: 3.763
Authors: Alison G Paquette; E Andres Houseman; Benjamin B Green; Corina Lesseur; David A Armstrong; Barry Lester; Carmen J Marsit Journal: Epigenetics Date: 2016-07-01 Impact factor: 4.528